A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma
A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)
Overall response rate (ORR). ORR defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the 2016 International Myeloma Working Group (IMWG) criteria assessed by Independent Review Committee (IRC).
6 months after the Last Participant In (LPI) i.e., approximately 16 months
Overall response rate (ORR). ORR defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the 2016 International Myeloma Working Group (IMWG) criteria assessed by Independent Review Committee (IRC).
6 months after the Last Participant In (LPI) i.e., approximately 16 months
Secondary Outcomes (2)
1. Proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6. Patient preference for method of administration defined as the proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6 using the patient experience and satisfaction questionnaire version 2 (PESQ v2).
2. Incidence rate of infusion reactions (IRs).
3. Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and changes in laboratory parameters.
4. Incidence rate of injection site reactions (ISRs).
5. PK concentration: trough plasma concentration (Ctrough). Blood samples will be collected for measurement of isatuximab concentrations.
6. Proportion of participants with sCR, CR, VGPR, and PR according to the 2016 IMWG criteria assessed by IRC.
7. Duration of response (DOR). DOR defined as time from date of first IRC-determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by IRC or death, whichever occurred first.
8. Time to first response (TT1R). TT1R defined as time from randomization to first IRC determined response (PR or better) that is subsequently confirmed.
9. Time to best response (TTBR). TTBR defined as time from randomization to first occurrence of IRC determined best response (PR or better) that is subsequently confirmed.
10. Progression free survival (PFS). PFS defined as time from the date of randomization to the date of first documentation of PD as determined by IRC or the date of death from any cause, whichever comes first.
11. Overall survival (OS). OS defined as time from the date of randomization to death from any cause.
12. Incidence of participants with anti-drug antibodies (ADA) against isatuximab.
13. Patient Expectations Questionnaire at Baseline (PEQ-BL v2) with isatuximab administered subcutaneously. PEQ-BL v2 is a participant assessed questionnaire. It will be completed at baseline prior to study treatment administration or other study related procedures. This questionnaire has been designed to assess the expectations of the participants regarding both the treatment (side effects, worth taking) and the administration method (confidence, comfortability, pain, side effects, potential time-savings), as well as to understand previous treatment experience from the participant (experience with injection methods for oncology medication).
14. Patient experience and satisfaction questionnaires (PESQ v2) with isatuximab administered subcutaneously. PESQ v2 is a participant assessed questionnaire. It has been designed to follow up on participant experience and satisfaction regarding the treatment (side effects, worth taking and overall satisfaction) and the administration method (confidence, comfortability, pain, side effects, potential time-savings and overall satisfaction). The PESQ v2 includes items to assess preference on subcutaneous injection method (manual and OBDS).
15. Health state utility assessed using Health Resource Utilization and Productivity Questionnaire (HRUPQ). Medical resource utilization and participant productivity will be collected from participants through a specific questionnaire developed by Sanofi. The data collected include number, nature (emergency or routine) and duration of hospitalizations, emergency room visits and outpatient medical encounters and employment history.
16. Health Related Quality of Life (HRQL). HRQL is assessed using the European Organization for Research and Treatment of Cancer (EORTC) myeloma module with 20 items (QLQ-MY20) and EORTC quality of life questionnaire with 30 questions (QLQ-C30); a total of 50 items. The EORTC QLQ-C30 provides a comprehensive assessment of the principal HRQL dimensions identified as relevant by cancer patients. The EORTC QLQ-MY20 is to be used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impact HRQL in participants with MM.
17. European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ5D-5L). Health status is assessed using the EQ-5D-5L, a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The VAS records the respondent’s self-rated health on a 20 cm vertical VAS with endpoints labelled ‘the best health you can imagine’ and ‘the worst health you can imagine’. This information can be used as a quantitative measure of health as judged by the individual respondents.
Interventions
isatuximabType not reported
CZ national declaration; IMP IMP:1; role: Test. Product, formulation and active substances are separate source declarations.
isatuximabBiological
CZ national declaration; named active substance (D.3.8) in IMP IMP:1 (isatuximab)
carfilzomib
Eligibility Criteria
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
You may qualify if:
[CZ]
Participants must have a documented diagnosis of multiple myeloma (MM)
Sponsors & Collaborators
Sanofi-aventis recherche & developpement
Type not reportedsponsor
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Central Study Contacts
Clinical Study Unit
SPONSOR CONTACT
Αγγελίνα Μαυράκη
SPONSOR CONTACT
Study Design
Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
PARALLEL
Number of Groups
4
Sponsor Type
INDUSTRY
Study Record Dates
Source record
Download the complete EU Clinical Trials Register record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), EU Clinical Trials Register / EudraCT. Country-specific registry documents are preserved with their source URLs and retrieval dates; conflicting national declarations are not combined.
The source bundle preserves the original country texts with attribution and retrieval details. Normalized values are available separately.
1. 6 months from LPI i.e., approximately 16 months
2, 4, 6, 7, 8, 9, 10, 11, 14, 15, 16, 17. 18 months after LPI i.e., approximately 28 months
3. From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months
5. Cycle 2 Day 1 and Cycle 6 Day 1 (1 Cycle = 28 days)
12. From Cycle 1 Day 1 to follow-up (90 days from last administration) i.e., approximately 13 months (1 Cycle = 28 days)
13. Baseline
1. Proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6. Patient preference for method of administration defined as the proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6 using the patient experience and satisfaction questionnaire version 2 (PESQ v2).
2. Incidence rate of infusion reactions (IRs).
3. Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and changes in laboratory parameters.
4. Incidence rate of injection site reactions (ISRs).
5. PK concentration: trough plasma concentration (Ctrough). Blood samples will be collected for measurement of isatuximab concentrations.
6. Proportion of participants with sCR, CR, VGPR, and PR according to the 2016 IMWG criteria assessed by IRC.
7. Duration of response (DOR). DOR defined as time from date of first IRC-determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by IRC or death, whichever occurred first.
8. Time to first response (TT1R). TT1R defined as time from randomization to first IRC determined response (PR or better) that is subsequently confirmed.
9. Time to best response (TTBR). TTBR defined as time from randomization to first occurrence of IRC determined best response (PR or better) that is subsequently confirmed.
10. Progression free survival (PFS). PFS defined as time from the date of randomization to the date of first documentation of PD as determined by IRC or the date of death from any cause, whichever comes first.
11. Overall survival (OS). OS defined as time from the date of randomization to death from any cause.
12. Incidence of participants with anti-drug antibodies (ADA) against isatuximab.
13. Patient Expectations Questionnaire at Baseline (PEQ-BL v2) with isatuximab administered subcutaneously. PEQ-BL v2 is a participant assessed questionnaire. It will be completed at baseline prior to study treatment administration or other study related procedures. This questionnaire has been designed to assess the expectations of the participants regarding both the treatment (side effects, worth taking) and the administration method (confidence, comfortability, pain, side effects, potential time-savings), as well as to understand previous treatment experience from the participant (experience with injection methods for oncology medication).
14. Patient experience and satisfaction questionnaires (PESQ v2) with isatuximab administered subcutaneously. PESQ v2 is a participant assessed questionnaire. It has been designed to follow up on participant experience and satisfaction regarding the treatment (side effects, worth taking and overall satisfaction) and the administration method (confidence, comfortability, pain, side effects, potential time-savings and overall satisfaction). The PESQ v2 includes items to assess preference on subcutaneous injection method (manual and OBDS).
15. Health state utility assessed using Health Resource Utilization and Productivity Questionnaire (HRUPQ). Medical resource utilization and participant productivity will be collected from participants through a specific questionnaire developed by Sanofi. The data collected include number, nature (emergency or routine) and duration of hospitalizations, emergency room visits and outpatient medical encounters and employment history.
16. Health Related Quality of Life (HRQL). HRQL is assessed using the European Organization for Research and Treatment of Cancer (EORTC) myeloma module with 20 items (QLQ-MY20) and EORTC quality of life questionnaire with 30 questions (QLQ-C30); a total of 50 items. The EORTC QLQ-C30 provides a comprehensive assessment of the principal HRQL dimensions identified as relevant by cancer patients. The EORTC QLQ-MY20 is to be used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impact HRQL in participants with MM.
17. European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ5D-5L). Health status is assessed using the EQ-5D-5L, a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The VAS records the respondent’s self-rated health on a 20 cm vertical VAS with endpoints labelled ‘the best health you can imagine’ and ‘the worst health you can imagine’. This information can be used as a quantitative measure of health as judged by the individual respondents.
1. 6 months from LPI i.e., approximately 16 months
2, 4, 6, 7, 8, 9, 10, 11, 14, 15, 16, 17. 18 months after LPI i.e., approximately 28 months
3. From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months
5. Cycle 2 Day 1 and Cycle 6 Day 1 (1 Cycle = 28 days)
12. From Cycle 1 Day 1 to follow-up (90 days from last administration) i.e., approximately 13 months (1 Cycle = 28 days)
13. Baseline
Type not reported
GR national declaration; IMP IMP:2; role: Test. Product, formulation and active substances are separate source declarations.
carfilzomibBiological
GR national declaration; named active substance (D.3.8) in IMP IMP:2 (carfilzomib)
dexamethasoneType not reported
GR national declaration; IMP IMP:3; role: Test. Product, formulation and active substances are separate source declarations.
dexamethasoneDrug
GR national declaration; named active substance (D.3.8) in IMP IMP:3 (dexamethasone)
dexamethasoneType not reported
GR national declaration; IMP IMP:4; role: Test. Product, formulation and active substances are separate source declarations.
dexamethasoneDrug
GR national declaration; named active substance (D.3.8) in IMP IMP:4 (dexamethasone)
carfilzomibType not reported
CZ national declaration; IMP IMP:2; role: Test. Product, formulation and active substances are separate source declarations.
carfilzomibBiological
CZ national declaration; named active substance (D.3.8) in IMP IMP:2 (carfilzomib)
dexamethasoneType not reported
CZ national declaration; IMP IMP:3; role: Test. Product, formulation and active substances are separate source declarations.
dexamethasoneDrug
CZ national declaration; named active substance (D.3.8) in IMP IMP:3 (dexamethasone)
dexamethasoneType not reported
CZ national declaration; IMP IMP:4; role: Test. Product, formulation and active substances are separate source declarations.
dexamethasoneDrug
CZ national declaration; named active substance (D.3.8) in IMP IMP:4 (dexamethasone)
isatuximabType not reported
GR national declaration; IMP IMP:1; role: Test. Product, formulation and active substances are separate source declarations.
isatuximabBiological
GR national declaration; named active substance (D.3.8) in IMP IMP:1 (isatuximab)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Participants with measurable disease defined as at least one of the following:
Serum M-protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
Urine M-protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65).
Participant with relapsed and/or refractory MM with at least 1 prior line of therapy and no more than 3 prior lines of therapy.
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and either is not a female of childbearing potential (FCBP) or agrees to practice complete abstinence or use approved contraception methods.
Male participants agree to practice true abstinence or agree to use approved contraception methods while receiving study treatment, during dose interruptions and at least 3 months following study treatment discontinuation, even if has undergone a successful vasectomy.
Capable of giving signed informed consent.
[GR]
Participants must have a documented diagnosis of multiple myeloma (MM)
Participants with measurable disease defined as at least one of the following:
Serum M-protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
Urine M-protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
+5 more criteria
You may not qualify if:
[CZ]
Primary refractory MM defined as participants who have never achieved at least a minimal response (MR) with any treatment during the disease course
Participants with prior anti-CD38 treatment are excluded if: a) Progression on or within 60 days after end of anti-CD38 mAb treatment or failure to achieve at least MR to treatment (ie, refractory to anti-CD38) with a washout period inferior to 9 months before the first isatuximab administration or, b) Intolerant to the anti-CD38 previously received
Prior treatment with carfilzomib
Known history of allergy to captisol (a cyclodextrin derivative used to solubilize carfilzomib), prior hypersensitivity to sucrose, histidine (as base and hydrochloride salt), polysorbate 80, or any of the components (active substance or excipient) of study treatment that are not amenable to premedication with steroids, or intolerance to arginine and Poloxamer 188 that would prohibit further treatment with these agents
Uncontrolled or active infection with hepatitis A, B, and C virus; known acquired immunodeficiency syndrome (AIDS)-related illness; active primary amyloid light chain (AL) amyloidosis
Any severe acute or chronic medical condition which could impair the ability of the participant to participate in the study or interfere with interpretation of study results (eg, systemic infection unless specific anti-infective therapy is employed) or participant unable to comply with the study procedures.
The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
[GR]
Primary refractory MM defined as participants who have never achieved at least a minimal response (MR) with any treatment during the disease course
Participants with prior anti-CD38 treatment if: a) administered < 9months before first isatuximab administration or randomization as
applicable or b) Intolerant to the anti-CD38 previously received
Prior treatment with carfilzomib
Known history of allergy to captisol (a cyclodextrin derivative used to solubilize carfilzomib), prior hypersensitivity to sucrose, histidine (as base and hydrochloride salt), polysorbate 80, or any of the components (active substance or excipient) of study treatment that are not amenable to premedication with steroids, or intolerance to arginine and Poloxamer 188 that would prohibit further treatment with these agents
Uncontrolled or active infection with hepatitis A, B, and C virus; known acquired immunodeficiency syndrome (AIDS)-related illness; active primary amyloid light chain (AL) amyloidosis
+2 more criteria
Contact the study team to confirm eligibility.
EU CTR national protocol (GR)
Registry countries
Countries publishing national protocol documents. This does not establish the number of recruiting sites.